The Medical Services Advisory Committee has responded to the health minister's assessment of its decision-making as "clunky" and causing deaths due to delays in funded access by deferring an outcome on the therapy that was the source of the critique.
MSAC doubles-down and defers outcome despite minister's criticism of delays and deaths
February 23, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
OncoSil charts a new growth phase as Chairman outlines progress and opportunities
November 19, 2025 - - Latest News -
CSL unveils US expansion, cementing its position as a global biopharma leader
November 19, 2025 - - Latest News -
Cleo Diagnostics appoints U.S. oncologist as first key opinion leader
November 19, 2025 - - Australian Biotech -
IDT Australia resets strategy as advanced therapies drive new phase of growth
November 19, 2025 - - BioPharma -
Dimerix Phase 3 kidney trial clears seventh safety review
November 19, 2025 - - Australian Biotech -
Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas
November 19, 2025 - - Australian Biotech -
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech